Loading clinical trials...
Loading clinical trials...
A Phase II Single-arm Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression After First-line EGFR-TKI Therapy
Conditions
Interventions
Furmonertinib
Locations
1
China
Sun yat-sen University Cancer Center
Guangzhou, Guangdong, China
Start Date
June 1, 2021
Primary Completion Date
January 31, 2024
Completion Date
May 31, 2024
Last Updated
July 21, 2021
NCT06043817
NCT07144280
NCT07431827
NCT06758401
NCT06427941
NCT06476808
Lead Sponsor
Sun Yat-sen University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions